NASDAQ · LMNL
Healthcare · Biotechnology
$8.50
Up+$0.01 (+0.12%)
Updated Aug 25, 2026, 12:11 PM
SID Score
—
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 0 trading sessions · Daily adjusted prices
LMNL does not have enough price history for the selected period.
Data unavailable
Market data is busy. Please try again shortly.
The latest Smart Investors Daily articles mentioning LMNL.
LMNL research
Company profile and research snapshot.
Liminal BioSciences Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel small molecule drug therapeutics for inflammatory, fibrotic, and metabolic diseases in Canada and the United Kingdom. The company's lead product candidate is fezagepras (PBI-4050), which has been completed Phase I clinical trial for the treatment of idiopathic pulmonary, liver, cardiac, or skin fibrosis with fezagepras or related derivatives and respiratory diseases. It is also developing antagonist candidate programs, including G-protein coupled receptor 84 and Oxo-eicosanoid receptor 1, which are in preclinical stage. The company was formerly known as Prometic Life Sciences Inc. and changed its name to Liminal BioSciences Inc. in October 2019. Liminal BioSciences Inc. was incorporated in 1994 and is headquartered in Laval, Canada.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Jun 24, 2021 | HC Wainwright & Co. | Neutral | — |
| Jun 2, 2021 | Piper Sandler | Neutral | — |
| Feb 18, 2021 | HC Wainwright & Co. | Buy | — |
| Dec 21, 2020 | Piper Sandler | Overweight | — |
No generated briefing is available yet.
Zacks Investment Research · Jul 13, 2023
If the minority shareholders of Liminal BioSciences (LMNL) accept the buyout offer, they will receive $8.50 per share. This offer is a dollar more than the initial proposal received by management in April.
MarketWatch · Apr 5, 2023
U.S. stocks traded mostly lower on Wednesday as investors weighed data on private-sector employment and the services index, while awaiting a March jobs report that will be released on Good Friday, a market holiday.
Zacks Investment Research · May 13, 2022
Liminal BioSciences Inc. (LMNL) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.
Zacks Investment Research · Nov 4, 2021
Liminal BioSciences Inc. (LMNL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning LMNL.
No results
No recent SID articles mention LMNL.
